Genus plc (LON:GNS – Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of GBX 1,818.83 ($23.55) and traded as high as GBX 1,970 ($25.50). Genus shares last traded at GBX 1,952 ($25.27), with a volume of 7,896,197 shares.
Analyst Ratings Changes
Separately, Shore Capital reaffirmed a “buy” rating on shares of Genus in a research note on Wednesday, December 11th.
Get Our Latest Analysis on Genus
Genus Trading Up 0.4 %
Genus (LON:GNS – Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.52) earnings per share for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. Research analysts expect that Genus plc will post 70.9644323 EPS for the current fiscal year.
Insiders Place Their Bets
In other Genus news, insider Jorgen Kokke sold 19,967 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of GBX 1,731 ($22.41), for a total value of £345,628.77 ($447,473.81). Insiders own 0.75% of the company’s stock.
Genus Company Profile
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
See Also
- Five stocks we like better than Genus
- Following Congress Stock Trades
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- What Are Some of the Best Large-Cap Stocks to Buy?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- What Are Dividend Challengers?
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.